Healthy
Conditions
Keywords
elderly
Brief summary
Nutrimemo aims to study the effect of a daily consumption of a mix of vitamin A and long chain n-3 Polyunsaturated Fatty Acids (PUFA) on the evolution of cognitive functions in healthy elderly subjects. The study is a randomized, double bind, parallel-groups (2 arms) placebo-controlled design.
Detailed description
This project aims to investigate the effects of 12 months supplementation with a mix of Vitamin A + Long chain n-3 PUFA vs placebo to consume daily on human cognitive functions. Food supplement and placebo will be provided as capsules matched for appearance. The study will be conducted as a randomized, double-blind, parallel-groups (2 arms) placebo-controlled. Two groups, each of 180 volunteers, are recruited. One group of volunteers will consume the Vitamin A + Long chain n-3 PUFA mix while the other one will consume the placebo product. Each volunteer will be seen for 5 visits at the investigational site. Baseline and the last follow-up visit will include cognitive assessment with the CANTAB battery. CANTAB tests will cover several aspects of memory: visio-spatial learning and episodic memory, visio-spatial working memory, frontal executive functions, but also word-based semantic memory. Moreover, psychological and mood components will be evaluated (mnesic complaint, depression, fatigue). Physical activity will also be recorded. Finally, biological parameters will be assessed (lipid profile, glycemia, CRP, thyroid stimulating hormone, transthyretin, plasma level of vitamin A and D as well as retinol binding protein and lipidic profile).
Interventions
DIETARY_SUPPLEMENTVitamin A +Long chain PUFA
3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
OTHERPlacebo
3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
Sponsors
University of Bordeaux
Unither Pharmaceuticals, France
Company Groupe St Hubert France
VAB Nutrition France
ITERG
Nutrimemo Consortium
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
60 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Independent subjects * Living at home non diagnosed as Alzheimer * Body Mass Index (BMI) 20-30 kg/m2 (limits included); * 26 \< MMSE score ≤ 29 * Logical memory subtest of the Wechsler Memory Scale (16-69 years battery) - sub-scores complying with the following: * Immediate recall score \< 29; * Delayed recall score \< 16;
Exclusion criteria
* Evidence of actual major depressive disorder according to the module A of the Mini International Neuropsychiatric Interview (MINI); * Subject consuming food supplements likely to have an effect on memory or within less than 6 months; * Subject consuming high level of Vitamin A and/or Long chain n-3 PUFA evaluated by a food frequency questionnaire, * Restrictive or unbalanced diet (hypocaloric, vegetarian, vegan, …) self-declared at V0; * Alcohol consumption \> 4 glasses/day * Diabetes; * Cardiovascular disease diagnosed within less than 2 years, with the following exceptions: subjects with controlled (medicated) high blood pressure and/ or controlled (medicated) can be included; * Unbalanced thyroid disease; * Anti-depressant treatment stopped since less than 3 months or still ongoing; * Personal history of schizophrenia or other psychiatric disorders; * Ongoing neuroleptic treatment; * Uncorrected visual or auditory dysfunction (according to the volunteer's self-declaration); * Life threatening pathology (such as cancer) in remission for less than 1 year or still ongoing; * General anesthesia in the last 6 months or planned in the next 6 months; * Documented food allergy(ies), namely to one of the components of the study product; * Psychological or linguistic incapability to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline of the episodic memory measured by CANTAB - Paired Associate Learning test (PAL) | 52 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline of the executive function and spatial planning measured by CANTAB - One tone Touch Stockings of cambridge (OTS) | 52 weeks | — |
| McNair scale | 52 weeks | The McNair and Kahn scale is a subjective scale used to evaluate the memory complaints in front of everyday conditions. |
| Change from baseline of the Verbal fluency measured by Isaac verbal fluency test | 52 weeks | Isaac verbal fluency test is a test for semantic memory and verbal fluency. The test consists to ask the patient to name in 15 seconds the most possible words around 4 semantic categories: colors, animals, fruits, cities (10 responses by category and score/40). |
| Montgomery et Asberg Depression Scale | 52 weeks | — |
| COVI anxiety Scale | 52 weeks | — |
| Change From Baseline in Mini-Mental State Examination (MMSE) | 52 weeks | The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline. |
| Multidimensional Fatigue Inventory (MFI-20) | 52 weeks | — |
| SF36 (Medical Outcome Study, Short-Form 36) | 52 weeks | — |
| blood lipidic profile | 52 weeks | Cholesterol g/L and Triglycerides g/L |
| Glycemia | 52 weeks | g/L |
| blood hight sensitive C reactive Protein (CRP) | 52 weeks | mg/L |
| Change From Baseline of the working memory measured by CANTAB - Spatial Span test (SSP) | 52 weeks | — |
| Blood retinol binding protein (RBP) | 52 weeks | mg/L |
| Blood transtyretin | 52 weeks | g/L |
| salivary cortisol | 52 weeks | nmol/L |
| blood free Thyroxine | 52 weeks | g/L |
| Blood triiodothyronine | 52 weeks | pg/MmL |
| blood Vitamin D 25 OH | 52 weeks | nmol/L |
| Fatty acid profile in erythrocyte membranes | 52 weeks | % of total fatty acids |
| Nuclear receptor mRNA expression in mononuclear cells | 52 weeks | relative expression |
| blood Inflammatory markers | 52 weeks | g/L |
| plasma beta amyloide | 52 weeks | pg/mL |
| blood Retinol | 52 weeks | µM/L |
Countries
France
Outcome results
None listed